Brief: Forty Seven & Ono Pharmaceutical Co Sign Regional License Agreement

ONO PHARMACEUTICAL

11/07/2019 12:08

July 11 (Reuters) - Forty Seven, Inc:
    * FORTY SEVEN, INC. AND ONO PHARMACEUTICAL CO., LTD. SIGN
REGIONAL
LICENSE AGREEMENT TO DEVELOP, MANUFACTURE AND COMMERCIALIZE 5F9
IN JAPAN, SOUTH KOREA, TAIWAN AND SELECT COUNTRIES IN SOUTHEAST
ASIA
    * FORTY SEVEN - CO TO GET UP TO $120 MILLION COMBINED
UPFRONT,
POTENTIAL DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS, IN
ADDITION TO ROYALTIES ON NET SALES
    * FORTY SEVEN INC - FORTY SEVEN WILL RECEIVE A ONE-TIME
UPFRONT
PAYMENT OF APPROXIMATELY $15.8 MILLION FROM ONO
    * FORTY SEVEN-ELIGIBLE TO RECEIVE UP TO ADDITIONAL ABOUT
$104
MILLION AT CURRENT EXCHANGE RATES IF SPECIFIED FUTURE
DEVELOPMENT MILESTONES ACHIEVED BY ONO
    * FORTY SEVEN INC - ONO WILL HAVE RIGHT TO PARTICIPATE IN
GLOBAL
CLINICAL STUDIES OF 5F9 BY BEARING DEVELOPMENT COST IN ABOVE
COUNTRIES
    * FORTY SEVEN INC - WILL RETAIN ALL RIGHTS TO 5F9 IN REST OF
WORLD
INCLUDING UNITED STATES, EUROPE AND CHINA
    * FORTY SEVEN INC - ONO TO RECEIVE EXCLUSIVE LICENSE FOR ALL
THERAPEUTIC USES OF 5F9 IN SELECT ASIAN MARKETS

Source text for Eikon:  ID:nGNX8tcm1S 
Further company coverage:  4528.T 

 ((Reuters.Briefs@thomsonreuters.com;))